New hope for brain lymphoma: drug combo targets tough cases
NCT ID NCT06552559
First seen Apr 24, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study tests a drug called selinexor combined with chemotherapy in 37 adults with B-cell lymphoma that has come back or not responded to treatment and has spread to the brain. The goal is to find the safest dose and see if the combination can shrink tumors. Selinexor works by trapping cancer-fighting proteins inside cells, and adding it to standard chemo may boost effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Cancer Research Institute
RECRUITINGSeoul, 135-710, South Korea
Contact Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, 135-710, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selinexor (a targeted drug) combined with chemotherapy (ifosfamide, carboplatin, etoposide, and dexamethasone)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat lymphoma that has spread to the brain, potentially improving survival.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.